The identification of driver mutations, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c‐ros oncogene 1 (ROS1), and the associated targeted therapies have improved outcomes for NSCLC patients.2, 3, 4, 5. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.